Recently, Aduhel (Aducanumab), a new drug for Alzheimer's disease approved by the U.S. Food and Drug Administration (FDA), has applied for permission in Korea.

Aduhel is a new drug for Alzheimer's disease approved by the U.S. FDA in 18 years, the first drug to target the amino acid peptide β-amyloid known to be involved in the disease.

The FDA approved after much meandering last month, but controversy still persists.

According to industry sources on the 15th, Biogen Korea recently applied for Aduhel's approval from the MFDS. Aduhel was approved by the U.S. Food and Drug Administration on the 7th (local time) on condition that a post-marketing investigation would prove it